Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh V. Ph D. Patel Sells 5,359 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh V. Ph D. Patel sold 5,359 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares of the company’s stock, valued at $20,627,126.80. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Protagonist Therapeutics Trading Up 0.7 %

Protagonist Therapeutics stock opened at $38.75 on Friday. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $48.89. The firm has a market cap of $2.31 billion, a P/E ratio of 14.57 and a beta of 2.22. The firm has a 50-day moving average of $38.41 and a 200-day moving average of $41.83.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on PTGX shares. Wedbush reissued an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday. StockNews.com cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. BMO Capital Markets began coverage on Protagonist Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $62.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTGX. FNY Investment Advisers LLC purchased a new position in Protagonist Therapeutics during the 4th quarter valued at $38,000. Exchange Traded Concepts LLC bought a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at about $43,000. GF Fund Management CO. LTD. purchased a new position in shares of Protagonist Therapeutics during the fourth quarter valued at about $48,000. CWM LLC raised its stake in Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after buying an additional 1,147 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in Protagonist Therapeutics by 5,200.0% in the fourth quarter. Covestor Ltd now owns 1,643 shares of the company’s stock worth $63,000 after buying an additional 1,612 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.